A Multi-zone Hvac System for a Typical Building for Matlab/simulink Platform

Matlab/Simulink is known in a large number of fields as a powerful and modern simulation tool. In the field of building and HVAC simulation its use is also increasing. However, it is still believed to be a tool for small applications due to its graphical structure and not to fit well for the simulation of multi-zone buildings. This paper presents the development of a new multi-zone building model for Matlab/Simulink platform

Removal of dye from synthetic textile wastewater using agricultural wastes and determination of adsorption isotherm

Reactive dyes have been applying extensively in textile industries. The treatment of textile industry waste waters is one of the main concerns of environmental health experts due to having excessive dyes and pollution. The aim of this study was to remove the Reactive Black 5 (RB5) dye from synthetic textile waste waters using agricultural wastes and determination of adsorption isotherm. In this research, Glycyrrhiza glabra root ash was prepared in laboratory condition and graded by standard sieve. The reactive Black 5 dye removals from textile synthetic wastewater using this adsorbent were tested. The effect of some parameters such as contact time (10–180 min), initial dye concentration (20, 40 and 60 mg/g) adsorbent dosage (0.2–2 g) and pH (2–12) were evaluated. Measurements were performed using an ultra violet-visible spectrophotometer at a wavelength of 597 nm and adsorption isotherm analyses were carried out. The results showed that data follow better the Langmuir adsorption model and the RL = 0.1123 was in the range of 0 to 1. Adsorption efficiency was reduced with increasing initial dye concentration and decreasing the adsorbent dosage. According to the results, the remaining root as an agricultural waste showed proper efficiency economically for the removal of dyes from textile industry wastewate

The short-term effects of intravitreal injection of bevacizumab on the plasma levels of vascular endothelial growth factor, insulin-like growth factor-1, and growth parameters in infants with retinopathy of prematurity

Purpose: To determine the changes in serum levels of free vascular endothelial growth factor (VEGF), insulin-like growth factor-1 (IGF-1), and growth parameters in infants with retinopathy of prematurity (ROP) who received intravitreal injection of the bevacizumab (IVB). Methods: A prospective interventional case series study, including 10 infants with Type 1 ROP was conducted. Using the enzyme-linked immunosorbent assay, serum levels of VEGF and IGF-1 were measured before, 1 month and 2 months after treatment with IVB in both eyes. Growth parameters, including weight, length, and head circumference and their Fenton's z-score, were also measured. Results: Serum VEGF levels were suppressed 1 month after IVB (P = 0.007) and then increased between 1 and 2 months (P = 0.064). Z-scores of all growth parameters except weight z-score decreased in the 1st and 2nd months. Conclusion: Serum VEGF levels showed a transient reduction after IVB which lasted at least 2 months. Growth velocity of premature infants may be affected by anti-VEGF therapy and should be followed with particular attention. © 2020 Journal of Current Ophthalmology | Published by Wolters Kluwer-Medknow

Two different doses of intravitreal bevacizumab for treatment of choroidal neovascularization associated with age-related macular degeneration

Purpose: To compare the efficacy and safety of 1.25 mg versus 2.5 mg intravitreal bevacizumab (IVB) for treatment of choroidal neovascularization (CNV) associated with agerelated macular degeneration (A). Methods: In this randomized clinical trial, consecutive patients with active CNV associated with A received 1.25 mg or 2.5 mg IVB. Best corrected visual acuity (BCVA), foveal thickness and side effects of therapy were evaluated one and three months after intervention. Results: Overall 86 subjects were enrolled and completed the scheduled follow-up. Forty seven and 39 patients received 1.25 and 2.5 mg IVB respectively. The study groups were balanced in terms of baseline characteristics such as age, BCVA and foveal thickness. Mean improvement in BCVA was 0.06±0.3 logMAR in the 1.25 mg group and 0.07±0.34 logMAR in the 2.5 mg group (P=0.9). Mean decrease in foveal thickness was 49±36 μm in the 1.25 mg group and 65±31μm in the 2.5 mg group (P=0.6). Three cases of vitreous reaction and one case of massive subretinal hemorrhage were observed in the 2.5 mg group. Conclusion: Double dose (2.5 mg) IVB does not seem to be more effective than regular dose (1.25 mg) injections for treatment of CNV due to A and may lead to more complications

Diabetic retinopathy clinical practice guidelines: Customized for Iranian population

Purpose: To customize clinical practice guidelines (CPGs) for management of diabetic retinopathy (DR) in the Iranian population. Methods: Three DR CPGs (The Royal College of Ophthalmologists 2013, American Academy of Ophthalmology Preferred Practice Pattern 2012, and Australian Diabetes Society 2008) were selected from the literature using the AGREE tool. Clinical questions were designed and summarized into four tables by the customization team. The components of the clinical questions along with pertinent recommendations extracted from the above-mentioned CPGs; details of the supporting articles and their levels of evidence; clinical recommendations considering clinical benefts, cost and side effects; and revised recommendations based on customization capability (applicability, acceptability, external validity) were recorded in 4 tables, respectively. Customized recommendations were sent to the faculty members of all universities across the country to score the recommendations from 1 to 9. Results: Agreed recommendations were accepted as the fnal recommendations while the non-agreed ones were approved after revision. Eventually, 29 customized recommendations under three major categories consisting of screening, diagnosis and treatment of DR were developed along with their sources and levels of evidence. Conclusion: This customized CPGs for management of DR can be used to standardize the referral pathway, diagnosis and treatment of patients with diabetic retinopathy. © 2016 Journal of Ophthalmic and Vision Research